Spoken Alpha
VERACYTE, INC.
Veracyte provides molecular diagnostic tests that help clinicians make treatment decisions for cancer patients. The company offers laboratory-developed tests in the U.S. through CLIA-certified labs for prostate, thyroid, bladder, and breast cancers, and distributes in vitro diagnostic tests internationally.
VERACYTE, INC is a Healthcare company operating in Diagnostics & Research with a $3.29B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 2, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VCYT.
$ curl https://api.spokenalpha.com/v1/companies/VCYTFAQ
Spoken Alpha indexes VCYT's earnings call transcripts at https://spokenalpha.com/companies/VCYT. Each call links to attributed speakers and parsed analyst Q&A.
VERACYTE, INC. (VCYT) held its most recent earnings call on 2026-07-30, covering fiscal Q2 2026.
VERACYTE, INC. (VCYT) operates in the Healthcare sector (Diagnostics & Research industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-02 | — | $0.28 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $0.37 | $0.29 | +27.6% | $150.3M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.52 | $0.33 | +57.6% | $139.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $0.53 | $0.39 | +35.9% | $140.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.51 | $0.32 | +59.4% | $131.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.44 | $0.30 | +46.7% | $130.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.31 | $0.20 | +55.0% | $114.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $0.36 | $0.26 | +40.0% | $118.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.33 | $0.17 | +94.1% | $115.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $0.30 | $-0.01 | +100.0% | $114.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $0.04 | $-0.10 | +100.0% | $96.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.39 | $-0.09 | -100.0% | $98.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.41 | $-0.13 | -100.0% | $90.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.12 | $-0.14 | +14.3% | $90.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.11 | $-0.11 | 0.0% | $82.4M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-0.05 | $-0.15 | +66.7% | $80.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-0.12 | $-0.23 | +47.8% | $75.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-01 | $-0.13 | $-0.22 | +40.9% | $72.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-0.20 | $-0.23 | +13.0% | $67.8M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.15 | $-0.16 | +6.3% | $67.3M | — | — | EODHD |
Source: EODHD. VCYT reported actuals as published; sparse fields render as —.